Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392794 | 0.82 | KMT2A (0.40) | TSHRMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL25542747 | 0.81 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1LMNANPC1 | |
| SCHEMBL21392800 | 0.78 | ALDH1A1 (0.49) | BCL2A1MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL23820824 | 0.75 | BCL2A1 (0.55) | BCL2A1TSHRTGM2PKMTRPM8 | |
| SCHEMBL1365648 | 0.72 | TSHR (0.66) | BCL2A1TSHRTGM2PKMTRPM8 | |
| SCHEMBL1359540 | 0.71 | BCL2A1 (0.61) | BCL2A1TSHRTGM2PKMTRPM8 | |
| SCHEMBL22699297 | 0.70 | SLC2A1 (0.43) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL172571 | 0.69 | THRB (0.54) | BCL2A1TSHRTGM2PKMMEN1 | |
| SCHEMBL21393105 | 0.68 | CA1 (0.41) | MEN1KMT2AALDH1A1HPGDMAPT | |
| SCHEMBL2117365 | 0.68 | SMN1; SMN2 (0.47) | KMT2AALDH1A1HPGDNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| US-12161648-B2 | Covalent targeting of E3 ligases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3863642-A1 | COVALENT TARGETING OF E3 LIGASES | The Regents of the University of California (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113164495-A | Covalent targeting of E3 ligase | 加利福尼亚大学董事会 | 2021-07-23 | — | — | CN | disclosed |
| WO-2019183600-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161648-B2 | Covalent targeting of E3 ligases | RNF114, RNF4, RNF168 | BCL2A1 1251/4885TSHR 4065/4885TGM2 3684/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | BCL2A1 919/4885TSHR 4601/4885TGM2 2225/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | BCL2A1 1251/4885TSHR 4065/4885TGM2 3684/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | BCL2A1 919/4885TSHR 4601/4885TGM2 2225/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | BCL2A1 1938/4885TSHR 4386/4885TGM2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.